Market cap
$485 Mln
Revenue (TTM)
$55 Mln
P/E Ratio
--
P/B Ratio
1.7
Div. Yield
0 %
| Prothena (PRTA) | Alkermes (ALKS) | GH Research PLC (GHRS) | |
|---|---|---|---|
Market cap ($ Mln) |
485 | 8,108 | 2,046 |
Revenue ($ Mln) |
55 | 1,668 | -- |
Net Profit ($ Mln) |
-43.99 | 66.12 | -62.27 |
Net Margin (%) |
-80.67 | 3.97 | -- |
RoE (%) |
-15.51 | 3.65 | -19.48 |
Price to Earnings |
-- | 127.18 | -- |
Price-To-Book |
1.69 | 4.48 | 5.48 |
Cashflow ($ Mln)
| Prothena (PRTA) | Alkermes (ALKS) | GH Research PLC (GHRS) | |
|---|---|---|---|
|
Cash From Operating Activities
|
-163.58 | 520.75 | -43.55 |
|
Cash Flow from Investing Activities
|
-0.14 | 295.50 | 46.17 |
|
Cash from Financing Activities
|
-0.14 | 12.38 | 139.65 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- |
Ratios
Profitability Ratios
| Prothena (PRTA) | Alkermes (ALKS) | GH Research PLC (GHRS) | |
|---|---|---|---|
|
ROCE (%)
|
-61.63 | 14.09 | -20.99 |
|
ROE (%)
|
-15.51 | 3.65 | -19.48 |
|
ROA (%)
|
-11.26 | 1.52 | -17.58 |
|
EBIT Margin (%)
|
-79.97 | 9.38 | -- |
|
Net Margin (%)
|
-80.67 | 3.97 | -- |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | -- |
Growth Ratios
| Prothena (PRTA) | Alkermes (ALKS) | GH Research PLC (GHRS) | |
|---|---|---|---|
|
Revenue Growth (%)
|
427.32 | 10.79 | -- |
|
EBIT Growth (%)
|
81.26 | -62.86 | -57.95 |
|
Net Profit Growth (%)
|
85.48 | -81.02 | -51.82 |
|
EPS Growth (%)
|
85.23 | -81.45 | -33.77 |
|
Book Value Growth (%)
|
-8.69 | 12.49 | 10.54 |
Valuation Ratios
| Prothena (PRTA) | Alkermes (ALKS) | GH Research PLC (GHRS) | |
|---|---|---|---|
|
Price / Earnings
|
-2.11 | 19.54 | -16.32 |
|
Price / Book Value
|
1.83 | 2.60 | 2.82 |
|
Dividend Yield (%)
|
-- | -- | -- |
|
EV/EBITDA
|
-1.12 | 10.49 | -10.69 |
|
Market Cap ($ Cr)
|
-- | -- | -- |
Solvency Ratios
| Prothena (PRTA) | Alkermes (ALKS) | GH Research PLC (GHRS) | |
|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.00 | 0.00 |
|
Short term debt to equity ratio
|
0.01 | 0.02 | 0.00 |
|
Current Ratio
|
25.05 | 2.30 | 28.70 |
|
Quick Ratio
|
25.05 | 1.85 | 28.70 |
|
Interest Coverage
|
-- | 2.65 | -308.80 |
Operating Efficiency Ratios
| Prothena (PRTA) | Alkermes (ALKS) | GH Research PLC (GHRS) | |
|---|---|---|---|
|
Debtors to sales (%)
|
0.00 | 27.37 | -- |
|
Asset Turnover
|
0.14 | 0.38 | 0.00 |
|
Receivable days
|
0.00 | 89.53 | -- |
|
Inventory Days
|
-- | 352.79 | -- |
|
Payable days
|
673.13 | 142.77 | 4,096.25 |
|
Cash Conversion Cycle
|
-- | 299.55 | -- |